Ironwood announces U.S. availability of Zurampic 200mg tablets
Ironwood Pharmaceuticals announced that ZURAMPIC is now available in pharmacies throughout the United States. ZURAMPIC is approved as a once-daily oral tablet to be taken in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia - high serum uric acid levels in the blood - associated with gout in patients who have not achieved target sUA levels with an XOI alone. ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia and should not be used as monotherapy. The safety and efficacy of ZURAMPIC were established in three Phase III, multicenter, randomized, double-blind, 12-month, placebo-controlled clinical studies in adult patients with hyperuricemia and gout. In two of the trials, ZURAMPIC was studied in combination with allopurinol and in a third trial was studied in combination with febuxostat. Most common adverse reactions with ZURAMPIC in the clinical trials were headache, influenza, blood creatinine increased, and gastroesophageal reflux disease.